Federal contract award
75F40124F19001
TO OBTAIN 7 SCIENTIFIC CONTRACT PROFESSIONALS TO SUPPORT THE RESEARCH PROGRAM OF THE FDA?S CENTER FOR DRUG EVALUATION AND RESEARCH, OFFICE OF BIOTECHNOLOGY PRODUCTS UNDER IDIQ CONTRACT 75F40124D00020.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541990 — All Other Professional, Scientific, and Technical Services |
| PSC | R799 — Other Management Support Services |
| Parent award / vehicle | 75F40124D00020 |
| Set-aside | Not reported |
| Pricing type | LABOR HOURS |
| Obligations | $3.2M |
| Current contract value | $3.2M |
| Potential contract value / ceiling | $3.2M |
| Start date | Jul 2, 2024 |
| Current end date | Jul 23, 2027 |
| Potential end date | Jul 23, 2027 |
| Latest award activity | Jun 18, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 18, 2026 | P00005 | $745.0K | TO OBTAIN 7 SCIENTIFIC CONTRACT PROFESSIONALS TO SUPPORT THE RESEARCH PROGRAM OF THE FDA'S CENTER FOR DRUG EVALUATION AND RESEARCH, OFFICE OF BIOTECHNOLOGY PRODUCTS-EXERCISE OP2 AND MODIFY OP2 POP. |
| Apr 14, 2026 | P00004 | $0 | TO OBTAIN 7 SCIENTIFIC CONTRACT PROFESSIONALS TO SUPPORT THE RESEARCH PROGRAM OF THE FDA'S CENTER FOR DRUG EVALUATION AND RESEARCH, OFFICE OF BIOTECHNOLOGY PRODUCTS. |
| Jul 21, 2025 | P00003 | $1.1M | MODIFICATION TO CHANGE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 30, 2025 AND EXERCISE OY1 |
| Dec 10, 2024 | P00002 | $0 | NO COST MODIFICATION TO CHANGE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 30, 2025. |
| Nov 4, 2024 | P00001 | $0 | NO COST MODIFICATION TO CHANGE PERIOD OF PERFORMANCE END DATE TO SEPTEMBER 30, 2025. |
| Jul 2, 2024 | 0 | $1.3M | TO OBTAIN 7 SCIENTIFIC CONTRACT PROFESSIONALS TO SUPPORT THE RESEARCH PROGRAM OF THE FDA?S CENTER FOR DRUG EVALUATION AND RESEARCH, OFFICE OF BIOTECHNOLOGY PRODUCTS UNDER IDIQ CONTRACT 75F40124D00020. |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
75/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 75/100. Available recorded signals: 70 points.
- Contract end 2027-07-23 (271 days from calculation)
- +35 points
- 152 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-06-18
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.